TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 ( 0.5 mg BID Titrated, 0.5 mg BID, 1 mg BID, and Titrated 1 mg BID ) in Smoking Cessation
Brief Summary: The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 ( 0.5 mg BID Titrated, 0.5 mg BID, 1 mg BID, and Titrated 1 mg BID ) in Smoking Cessation
Brief Summary: The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018


Options:
A: Arm Label: Combination zonisamide and bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Zonisamide, Other: E-cigarette | Arm Label: Bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Arm Label: Placebo with e-cigarette; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Placebo bupropion; Assigned to Arm(s): Placebo with e-cigarette | Intervention Type: DRUG; Name: Placebo zonisamide; Assigned to Arm(s): Bupropion with e-cigarette, Placebo with e-cigarette | Intervention Type: OTHER; Name: E-cigarette; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette, Placebo with e-cigarette
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Clinical Decision Support; Type: EXPERIMENTAL; Interventions: Other: Clinical Decision Support | Intervention Type: OTHER; Name: Clinical Decision Support; Assigned to Arm(s): Clinical Decision Support
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 ( 0.5 mg BID Titrated, 0.5 mg BID, 1 mg BID, and Titrated 1 mg BID ) in Smoking Cessation
Brief Summary: The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2
B: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Multi-center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).
Brief Summary: The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects sleep and how the participants perceive their quality of life.


Options:
A: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.; Assigned to Arm(s): N/A
D: Arm Label: AR11 (amphetamine sulfate) (1 week) - double blind; Type: EXPERIMENTAL; Interventions: Drug: AR11 | Arm Label: Placebo (1 week) - double blind; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AR11; Assigned to Arm(s): AR11 (amphetamine sulfate) (1 week) - double blind | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (1 week) - double blind

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Multi-center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).
Brief Summary: The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects sleep and how the participants perceive their quality of life.


Options:
A: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adderall-XR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Arm Label: Adderall-XR 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Adderall-XR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 60 mg | Intervention Type: DRUG; Name: Adderall-XR; Assigned to Arm(s): Adderall-XR 80 mg
C: Arm Label: Vyvanse; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vyvanse | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vyvanse; Assigned to Arm(s): Vyvanse | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Adderall Extended Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Arm Label: Adderall Immediate Release First; Type: EXPERIMENTAL; Interventions: Drug: Adderall ® Immediate Release, Drug: Adderall XR ® | Intervention Type: DRUG; Name: Adderall ® Immediate Release; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First | Intervention Type: DRUG; Name: Adderall XR ®; Assigned to Arm(s): Adderall Extended Release First, Adderall Immediate Release First

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, 12-Week, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of J867 on Uterine Artery Blood Flow and the Morphology of the Endometrium, Myometrium, and Uterine Leiomyomata in Subjects With Uterine Leiomyomata Scheduled for Hysterectomy.
Brief Summary: The objective of this study is to evaluate the effects of 10 mg and 25 mg doses of asoprisnil, compared to placebo, taken daily for 12 weeks, on uterine blood flow and the morphology of the endometrium and uterine fibroids.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Ulipristal acetate (PGL4001) 5mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 5 mg | Arm Label: Ulipristal acetate (PGL4001) 10mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 10 mg | Intervention Type: DRUG; Name: PGL4001 5 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 5mg | Intervention Type: DRUG; Name: PGL4001 10 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 10mg
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin | Intervention Type: DRUG; Name: PGL4001, placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin; Assigned to Arm(s): B
D: Arm Label: A (PGL4001 5 mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: C (GnRH-agonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: leuprorelin | Intervention Type: DRUG; Name: PGL4001; Assigned to Arm(s): A (PGL4001 5 mg), B (PGL4001 10mg) | Intervention Type: DRUG; Name: leuprorelin; Assigned to Arm(s): C (GnRH-agonist)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer
Brief Summary: This study aimed to verify the survival benefit of TS-1 plus CDDP combination chemotherapy compared with the monotherapy by TS-1 alone.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: TS-1 and cisplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: TS-1 | Intervention Type: DRUG; Name: TS-1 and cisplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: TS-1; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Benefit of STent Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR)
Brief Summary: Background:

Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipidlowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients.

Method:

Patients with an ARAS of ≥50% and renal failure (creatinine (Cr) clearance \<80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance \>20% compared to baseline. This trial will include 140 patients.


Options:
A: Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atacand/HCT, Caduet | Arm Label: Stenting; Type: EXPERIMENTAL; Interventions: Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) | Intervention Type: DRUG; Name: Atacand/HCT, Caduet; Assigned to Arm(s): Optimal Medical Therapy | Intervention Type: PROCEDURE; Name: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting); Assigned to Arm(s): Stenting
B: Intervention Type: PROCEDURE; Name: Angiographic renal revascularization; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Renal artery stent; Assigned to Arm(s): N/A
D: Arm Label: STN; Type: EXPERIMENTAL; Interventions: Device: Dynamic Renal Stent plus Best Medical Treatment | Arm Label: BMT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Medical Treatment | Intervention Type: DEVICE; Name: Dynamic Renal Stent plus Best Medical Treatment; Assigned to Arm(s): STN | Intervention Type: DRUG; Name: Best Medical Treatment; Assigned to Arm(s): BMT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automated Step-count Feedback to Promote Physical Activity in Diabetes
Brief Summary: The primary purpose of this study is to test an Internet based program along with an enhanced pedometer to promote walking in people with diabetes. The major research question to be answered is if counseling and feedback that emphasizes a 10-minute minimum duration for physical activity bouts result in a different pattern of walking behavior compared to counseling and feedback focusing only on total daily accumulated steps.


Options:
A: Arm Label: Feedback group; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of daily walking activity | Arm Label: No-feedback group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback of daily walking activity; Assigned to Arm(s): Feedback group
B: Arm Label: care guide; Type: EXPERIMENTAL; Interventions: Behavioral: education and care guide | Arm Label: no care guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education only | Intervention Type: BEHAVIORAL; Name: education and care guide; Assigned to Arm(s): care guide | Intervention Type: BEHAVIORAL; Name: education only; Assigned to Arm(s): no care guide
C: Intervention Type: BEHAVIORAL; Name: Tailored web-based walking program; Assigned to Arm(s): N/A
D: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Diabetes Education Program Evaluation
Brief Summary: The study is intended to determine the effectiveness and efficiency of a community diabetes education program administered by a community health worker in a low-cost community clinic. We expect an improvement in overall glycemic control in the experimental group of at least 20%. We also expect to document improvement in diabetes self-management skills, quality of life and an increase in achievement of ADA standards of care4 in the experimental group.


Options:
A: Arm Label: Telemedical Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedical coaching, Other: Telemedicine | Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedical coaching | Intervention Type: BEHAVIORAL; Name: Telemedical coaching; Assigned to Arm(s): Telemedical Coaching, Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedical Coaching
B: Intervention Type: BEHAVIORAL; Name: Education for diabetes self-management; Assigned to Arm(s): N/A
C: Arm Label: Routine general practice care; Type: NO_INTERVENTION; Interventions: Behavioral: Structured personal care | Intervention Type: BEHAVIORAL; Name: Structured personal care; Assigned to Arm(s): Routine general practice care
D: Arm Label: Technology-based self-management model; Type: EXPERIMENTAL; Interventions: Device: Technology-based self-management model | Arm Label: Conventional self-management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Technology-based self-management model; Assigned to Arm(s): Technology-based self-management model

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Diabetes Education Program Evaluation
Brief Summary: The study is intended to determine the effectiveness and efficiency of a community diabetes education program administered by a community health worker in a low-cost community clinic. We expect an improvement in overall glycemic control in the experimental group of at least 20%. We also expect to document improvement in diabetes self-management skills, quality of life and an increase in achievement of ADA standards of care4 in the experimental group.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Intervention Type: BEHAVIORAL; Name: Education for diabetes self-management; Assigned to Arm(s): N/A
C: Arm Label: care guide; Type: EXPERIMENTAL; Interventions: Behavioral: education and care guide | Arm Label: no care guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education only | Intervention Type: BEHAVIORAL; Name: education and care guide; Assigned to Arm(s): care guide | Intervention Type: BEHAVIORAL; Name: education only; Assigned to Arm(s): no care guide
D: Intervention Type: BEHAVIORAL; Name: Nurse Case Management intervention; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Valsartan in Elderly Isolated Systolic Hypertension
Brief Summary: The aim of this study is to compare the incidence of cardiovascular events between two target systolic blood pressure levels, below 140 mmHg and below 150 mmHg under treatment with valsartan in elderly isolated systolic hypertensive patients in Japan.


Options:
A: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
B: Arm Label: strict control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Arm Label: moderate control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Intervention Type: OTHER; Name: target blood pressure; Assigned to Arm(s): moderate control, strict control
C: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
D: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A

Answer: B